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Abstract
Extensive liver surgery for colorectal liver metastases (CRLM) is frequently performed, but data on the out-
comes of these complex surgical procedures are scarce. Here we report surgical and oncologic outcomes for
117 patients who underwent major liver surgery at a Dutch tertiary referral center. Major hepatic resection is
associated with considerable postoperative morbidity and mortality, but it can provide signiﬁcant long-term
survival for patients with CRLM.
Purpose: To determine the surgical and oncologic outcomes after major liver surgery for colorectal liver metastases
(CRLM) at a Dutch University Hospital. Patients and Methods: Consecutive patients with CRLM who had undergone
major liver resection, deﬁned as  4 liver segments, between January 2000 and December 2015 were identiﬁed from a
prospectively maintained database. Results: Major liver surgery was performed in 117 patients. Of these, 26 patients
had undergone formal extended left or right hemihepatectomy. Ninety-day postoperative mortality was 8%. Major
postoperative complications occurred in 27% of patients; these adverse events were more common in the extended
hemihepatectomy group. Median disease-free survival was 11 months and median overall survival 44 months.
Conclusion: Major liver surgery, including formal extended hemihepatectomy, is associated with signiﬁcant operative
morbidity and mortality but can confer prolonged overall survival for patients with CRLM.
Clinical Colorectal Cancer, Vol. 15, No. 4, e193-8 ª 2016 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Colorectal cancer, Hepatectomy, Metastasis, Morbidity, SurvivalIntroduction
Complete surgical resection is the only curative treatment option
for patients with colorectal liver metastases (CRLM). If left un-
treated, median survival after diagnosis of CRLM is less than 1
year.1 With a 5-year survival rate of up to 50%, surgical resection
signiﬁcantly improves the prognosis of these patients.2,3 The limited
criteria for partial liver resection (presence of a maximum of 3
metastases, absence of additional extrahepatic disease, and resection
margin > 10 mm4) have largely been abandoned. Resectability is
now deﬁned as the ability to surgically remove all visible liver me-
tastases with tumor-free margins while preserving adequate futureCancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
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http://dx.doi.org/10.1016/j.clcc.2016.04.006liver remnant volume (FLRV) with sufﬁcient vascular supply and
biliary drainage.3 Advances in surgical technique, use of preoperative
portal vein embolization (PVE) to induce compensatory hypertro-
phy for improvement of FLRV, and effectiveness of neoadjuvant
chemotherapeutic regimens have increased the number of patients
eligible for resection.5-7 Nevertheless, only 20% to 30% of patients
with liver metastases are potential candidates for resection.3,8
With the expanding indications for liver resection in patients
with CRLM, major hepatectomy, deﬁned as resection of 4 or more
liver segments9 and extended hemihepatectomies (ie, right or left
trisectionectomy10), are executed in most hepatobiliary tertiary
referral centers. Major liver resection remains a high-risk procedure,
however. The incidence of complications has been correlated to the
extent of liver surgery, with severe complications reported in up to
40% of patients undergoing major liver resection for CRLM.11-13
Despite improvement in perioperative management, the mortality
associated with extensive liver surgery has remained unchanged over
the past 20 years.14 Careful appraisal of the beneﬁts is thereforeClinical Colorectal Cancer December 2016 - e193
e194
Outcomes After Liver Surgeryessential. Data on the long-term outcomes of major liver surgery are
scarce, however, with only a few available reports from high-volume
centers that specialize in liver surgery.
Here we present the surgical and oncologic outcomes of major
liver resections, including extended hemihepatectomies, in patients
with CRLM from a large single-center cohort.
Patients and Methods
Study Population
From a prospective database, we identiﬁed patients undergoing
major liver surgery for CRLM with curative intent between January
2000 and December 2015 at the University Medical Center
Utrecht, the Netherlands. Major liver surgery is deﬁned as resection
of 4 or more liver segments.9
Data Collection
Demographic and clinicopathologic characteristics, including age,
sex, primary tumor characteristics, chemotherapeutic treatment,
PVE, number of CRLMs, type of liver surgery, resection margins,
postoperative mortality, disease-free survival (DFS), and overall
survival (OS) were collected prospectively.
Synchronous liver metastases were deﬁned as metastases detected
before or during primary tumor resection. The postoperative mor-
tality rate was assessed at 90 days after surgery. DFS and OS were
calculated from the date of hepatic resection to the date of ﬁrst
recurrence detected with radiologic imaging and death. If there were
no events, patients were censored at last follow-up. Patients whose
extrahepatic disease was not resected or who had a primary tumor
still in situ were excluded from the DFS analyses but included in the
OS analyses.
Data on duration of surgery, amount of blood loss, duration of
hospital and intensive care unit stay, and postoperative morbidity
were collected retrospectively. Postoperative complications were
independently graded according to the Clavien-Dindo classiﬁca-
tion15 by 2 researchers (I.U. and J.J.) on the basis of information
available from electronic medical records. In case of disagreement, a
third opinion (J.H.) was decisive. Only major complications
(Clavien-Dindo grades III to V) that occurred before ﬁrst hospital
discharge were recorded.
Hepatic Resection
Routine preoperative imaging included liver contrast-enhanced
3-phase computed tomography and thoracoabdominal spiral
computed tomographic scan to assess resectability, FLRV, and
extrahepatic metastases. Magnetic resonance imaging of the liver or
positron emission tomography were performed as indicated. Portal
vein embolization was carried out before surgery to improve FLRV
if indicated.
All resections were performed with curative intent by 4 expert
hepatic surgeons. After laparotomy, the abdomen was explored, and
intraoperative ultrasound was performed to determine the extent
and resectability of the metastases. Parenchymal transection was
performed with an ultrasonic dissector. To minimize blood loss,
central venous pressure was maintained below 5 mm Hg. Inter-
mittent portal triad clamping (Pringle maneuver) was applied if the
surgeons expected excessive blood loss.16 Hemostasis and biliostasis
were achieved with bipolar cautery coagulation, clips, or ligation.- Clinical Colorectal Cancer December 2016The Brisbane 2000 terminology10 was used to describe the type
of liver resections. Extended right hemihepatectomy (or right tri-
sectionectomy) requires en bloc resection of segment IV (a, b, or
both) in addition to right hemihepatectomy with or without
caudate resection. Extended left hemihepatectomy (or left tri-
sectionectomy) is deﬁned as left hepatectomy (segments I, II, III,
and IV) plus segments V and VIII. The resection specimen was
analyzed by an experienced pathologist to assess resection margins.
A resection is denoted R0 if all margins are free of tumor, R1 if there
is microscopic invasion of the resection surface, and R2 if the
resection is macroscopically not radical.
Statistical Analysis
Statistical analyses were performed by SPSS 20 (IBM SPSS,
Chicago, IL). The Pearson chi-square test was used to compare
differences in discrete or categorical data, whereas continuous data
were analyzed with the Mann-Whitney U test. DFS and OS curves
were generated using the Kaplan-Meier method; differences be-
tween survival curves were assessed by log rank test. A level of P <
.05 was considered statistically signiﬁcant.
Results
Patient and Oncologic Characteristics
Between January 2000 and December 2015, a total of 543 partial
hepatectomies were performed, of which 312 were performed for
CRLM. Repeat hepatectomies (n ¼ 33), 2-stage hepatectomies
(n ¼ 8), and resections in combination with hyperthermic intra-
peritoneal chemotherapy (n ¼ 1) were excluded from this analysis,
resulting in a cohort of 270 liver resections for CRLM. Of these,
117 (43%) were major hepatic resections. Patient and tumor
characteristics are listed in Table 1. The median age at time of liver
surgery was 63 years; 66% of patients were male. The majority of
primary tumors were located in the sigmoid and rectum. Half of the
patients presented with synchronous CRLM; 23 patients (9%) had
simultaneous extrahepatic disease. Neoadjuvant chemotherapy was
administered to 29% of all patients, more often before major
resection than minor hepatectomy (P ¼ .014). Patients with syn-
chronous CRLM had more often received neoadjuvant chemo-
therapy (P < .001). PVE to increase FLRV before liver resection
was performed in 12 patients.
Surgical Outcomes of Major Hepatectomy for CRLM
Of the 117 major liver resections, 26 procedures were formal
extended hemihepatectomies (right, n ¼ 22; left, n ¼ 4;
Table 2). Radiofrequency ablation in addition to major surgery
was performed in 9 patients, and liver surgery was combined
with resection of extrahepatic disease in 3 of 8 patients. The
majority of patients with synchronous CRLM were treated in the
traditional (primary tumor ﬁrst) order; the reversed, or liver-ﬁrst,
procedure, in which CRLM are resected before the primary
tumor, was used in 9 patients, of whom 5 underwent an
extended hemihepatectomy. The R0 resection rate was 90%
(Table 2).
Major postoperative complications (Clavien-Dindo grades III to
V) occurred in 27% of patients who underwent major resection. An
overview of these complications is shown in Table 3. The most
common adverse event was pleural effusion requiring
Table 1 Patient and Oncologic Characteristics
Characteristic All Resections (n [ 270) Minor Resections (n [ 153) Major Resections (n [ 117)
Age, years 63 (32-85) 64 (37-85) 62 (32-83)
Male gender 177 (66) 98 (65) 79 (67)
Primary Tumor
Locationa
Cecum þ right hemicolon 56 (21) 37 (24) 19 (17)
Left hemicolon 19 (7) 6 (4) 13 (11)
(Recto)sigmoid 93 (35) 55 (36) 38 (33)
Rectum 97 (37) 52 (34) 45 (39)
T stage T3/T4b 215 (88) 122 (89) 93 (88)
N status N1/N2c 155 (63) 84 (61) 71 (65)
Hepatic Metastases
Number 2 (1-20) 1 (1-10) 2 (1-20)
Synchronous metastases 136 (50) 71 (46) 65 (56)
Concomitant extrahepatic diseased 23 (9) 15 (10) 8 (7)
Neoadjuvant chemotherapye 78 (29) 33 (22) 45 (39)
Portal vein embolization 12 (4) 2 (1) 10 (9)
ASA Physical Status Classiﬁcationf
ASA 1 45 (25) 27 (27) 18 (23)
ASA 2 119 (67) 66 (65) 53 (69)
ASA 3 15 (8) 9 (9) 6 (8)
Data are presented as median (range) or n (%). Data are available for: a265, b243, c247, d266, e254, and f179 patients.
Abbreviation: ASA ¼ American Society of Anesthesiologists.
Inge Ubink et althoracocentesis. Major complications were more common after
formal extended hemihepatectomy compared to other major re-
sections (46% vs. 21% complication rate, respectively, P ¼ .01).
Patients treated with neoadjuvant chemotherapy more often expe-
rienced major complications, but this difference was not statistically
signiﬁcant (36% vs. 21% respectively, P ¼ .08). The occurrence of
major complications signiﬁcantly prolonged median intensive care
unit and hospital stay. Of the discharged patients, 15% were
readmitted to the hospital for unresolved or new complications.
The 90-day postoperative mortality rate after major liver surgery
was 8% compared to 2% in the minor resection group (P ¼ .02).
Causes of death after major resection were as follows: hepatic failure
(n ¼ 2), multiorgan failure (n ¼ 2), pancreatitis (n ¼ 1), acute
respiratory distress syndrome (n ¼ 2), pulmonary embolism (n ¼
1), and intra-abdominal hemorrhage (n ¼ 1).
Recurrence and OS
Median follow-up after major hepatectomy was 22.5 months
(range, 0.3-132 months). The median DFS was 11 months (95%
conﬁdence interval [CI], 7.3-15.3 months). One- and 3-year DFS
were 49% and 21%, respectively. Median OS was 44 months (95%
CI, 28.2-60.3 months). One-, 3-, and 5-year OS rates were 87%,
59%, and 40%, respectively. Patients who had received neo-
adjuvant therapy had a shorter median OS (35 months; 95% CI,
24-46 months), versus 73 months (95% CI, 32-114 months)
without chemotherapy (P ¼ .02). There were no signiﬁcant dif-
ferences in DFS and OS between minor and major liver resections
(Figure 1).Discussion
Extensive liver resections are frequently being performed for
CRLM; however, data on the short- and long-term oncologic out-
comes of these highly complex surgical procedures are scarce and are
almost exclusively reported by a few high-volume centers. This
leaves several vital questions regarding the potential risks and ben-
eﬁts of these procedures unanswered, encumbering patient coun-
seling and clinical decision making. Here we present data on surgical
and oncologic outcomes for 117 patients with metastatic CRLM
who underwent major liver resection (4 or more liver segments) at a
Dutch tertiary referral center.
Short-Term Outcomes
It has been shown that resection of 4 or more segments
signiﬁcantly increases the risk of postoperative morbidity and
mortality compared to less extensive resections.9,11,14 High
complication rates of major liver surgery have been reported by,
eg, Konopke et al11 (37%) and van Dam et al12 (33%). In our
cohort, 27% of the patients experienced grade III or higher
postoperative complications. The distribution of the observed
complications corresponds well with the complications found in a
recent study on predictors for complications after hemi-
hepatectomy.17 Patients who underwent extended hemi-
hepatectomy had signiﬁcantly more complications than patient
undergoing other major resections, which should be taken into
account when selecting patients for resection. Postoperative
complications led to death in 9 patients (8%) in this cohort,
which is comparable with other studies on major liver surgery forClinical Colorectal Cancer December 2016 - e195
Table 2 Perioperative Characteristics
Operative Characteristic All Resections (n [ 270) Minor Resections (n [ 153) Major Resections (n [ 117)
Type of Liver Resection
Extended left hepatectomy 4 (2) 0 (0) 4 (3)
Extended right hepatectomy 22 (8) 0 (0) 22 (19)
Left hemihepatectomy 24 (9) 0 (0) 24 (21)
Right hemihepatectomy 64 (24) 0 (0) 64 (55)
Multisegmentectomy (4) 3 (1) 0 (0) 3 (3)
Three segments 16 (6) 16 (11) 0 (0)
Two segments 42 (16) 42 (28) 0 (0)
One segment 43 (16) 43 (28) 0 (0)
Wedge resection 52 (19) 52 (34) 0 (0)
Combined primary D liver resection 5 (2) 5 (3) 0 (0)
Liver-ﬁrst procedure 13 (5) 4 (3) 9 (8)
Concomitant radiofrequency ablation 29 (11) 20 (13) 9 (8)
Surgery duration, minutesa 220 (70-540) 180 (70-420) 250 (120-540)
Pringle maneuverb 139 (52) 77 (63) 62 (55)
Blood loss, mLc 600 (0-12,150) 475 (0-11,000) 900 (100-12,150)
Postoperative Course
Hospital stay, days 9 (3-74) 8 (3-74) 12 (4-67)
ICU stay, days 1 (0-55) 1 (0-54) 1 (0-55)
Postoperative deaths 12 (4) 3 (2) 9 (8)
Readmissions 30 (11) 13 (8) 17 (15)
Resection Margins
R0 243 (90) 138 (90) 105 (90)
R1 26 (10) 15 (10) 11 (9)
R2 1 (0) 0 (0) 1 (1)
Data are presented as median (range) or n (%). Data are available for: a265, b235, and c183 patients.
Abbreviation: ICU ¼ intensive care unit.
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e196CRLM, with reported mortality rates between 0% and
10%.9,13,18-21 Over the past 2 decades, Kingham et al14 noted a
remarkable decline in postoperative complications and deaths
coinciding with a decrease in the number of major resections
performed. Preservation of hepatic parenchyma, by combining
resection with radiofrequency ablation or by expanding FLRV
with PVE, could thus limit postoperative morbidity and
mortality.
Long-Term Outcomes
Few studies have presented survival data on major liver surgery
for CRLM, deﬁned as resection of 4 or more liver segments. Five-
year DFS ranged from 4% to 25.5%; 5-year OS was reported
between 25% and 38.7%.18,19,22-24 Our survival results (3-year
DFS 21% and 5-year OS 40%) are in line with these reports.
In previous studies, major hepatectomy patients appear to have a
shorter survival compared to patients undergoing minor resection
for CRLM.18,22 Presumably this is due to a higher tumor burden,
considering that the number of metastases signiﬁcantly inﬂuences
OS.1 We did not observe differences in DFS or OS between
minor and major resections in our cohort; however, we did see a
correlation between the number of metastases and survival out-
comes (data not shown). The improvement in OS compared to- Clinical Colorectal Cancer December 2016palliative chemotherapy (median OS, 20-24 months25) indicates
that surgical resection, even if major or extended hepatectomy is
required, is the preferred treatment option for CRLM if possible.
Despite the fairly positive OS rate, DFS remains low in this
study, even though R0 resection was achieved in the majority of
patients.
Preoperative Chemotherapy
Neoadjuvant chemotherapy is considered for downsizing initially
unresectable CRLM; up to 23% of patients with initially unre-
sectable metastases can undergo macroscopic curative resection after
neoadjuvant therapy.6 Preoperative chemotherapy is also used in
patients with resectable disease to reduce the chances of post-
operative relapse, although recently no signiﬁcant survival beneﬁt
was found with the addition of perioperative chemotherapy
(FOLFOX4) compared to surgery alone for patients with resectable
liver metastases.2 Unfortunately, preoperative chemotherapy comes
at a cost: chemotherapy-induced hepatic injury increases the risk of
postoperative complications.26 In our cohort, we observed a trend
toward increased morbidity associated with neoadjuvant chemo-
therapy, but this was not statistically signiﬁcant. We did notice a
shorter OS in patients who had received preoperative chemo-
therapy. Cases were not matched, however, and we did not correct
Table 3 Speciﬁcation Grade 3 or Higher Postoperative
Complications
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Acute renal failure 1
Sepsis e causa ignota 1
Intra-abdominal hemorrhage 1
Pancreatitis 1
Gastric ulcer bleeding 1
Pericardial tamponade 1
Procedural complication: colon perforation 1
Inge Ubink et alfor potential confounding variables. A possible explanation for the
shorter OS is that these patients presented with initially unresectable
metastases, reﬂecting a more extensive tumor spread compared toFigure 1 Disease-Free (A) and Overall Survival (B) After Minor or Mpatients who did not require neoadjuvant chemotherapy. Indeed,
patients with primarily resectable disease had better OS than pa-
tients with down-staged metastases in a large series of CRLM.27
Nevertheless, survival outcome of resection after conversion
chemotherapy is better compared to survival after chemotherapy
alone.28
Even though this study is limited by the relatively small sample
size with patients from a single institution, and even though our
ﬁndings are from retrospective analysis of prospectively collected
data, the results of this study conﬁrm that major hepatic resection
and formal extended hemihepatectomy for the treatment of CRLM
can provide signiﬁcant long-term survival. As a result of the
complexity of the procedure, major liver surgery is associated with
relatively high postoperative morbidity and mortality. Determina-
tion of the appropriate treatment sequence for synchronous liver
metastases, increasing efforts to perform parenchymal-sparing re-
sections, and further improvement in selection of patients suitable
for major hepatic resection should reduce the complication rate and
ameliorate DFS and OS.
Clinical Practice Points
 The results of this study conﬁrm that major hepatic resection,
including extended hemihepatectomy, can provide signiﬁcant
long-term survival for patients with CRLM.
 The improvement in median OS after extensive liver surgery (40
months in our study), compared to survival rates reported for
palliative chemotherapy (20-24 months), indicates that major or
extended hepatectomy should deﬁnitely be considered as a
treatment option for CRLM.
 Major liver surgery remains associated with considerable peri-
operative morbidity and mortality. Careful patient selection and
increasing efforts to perform parenchymal-sparing resections
should reduce the complication rate and further ameliorate DFS
and OS.ajor Hepatectomy for Colorectal Liver Metastases
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